3 withdrawn, 2 completed, 2 terminated, 1 recruiting. 7 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Withdrawn 3, Terminated 2, Completed 1, Recruiting 1 |
| Phase 1 | 5 | Completed 2, Withdrawn 2, Terminated 1 |
Follow CPI 613: new trials by email Literature Review of CPI 613 trials Research Report on CPI 613
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) CPI 613, Metformin, Blood draws - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2024-12-01 | 2024-09-19 | |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma CPI 613, Bendamustine - Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 6 | 2020-09-16 | 2025-05-02 |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) CPI 613, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 75 | 2020-06-23 | 2025-12-31 |
| CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer CPI 613, Oxaliplatin, Irinotecan - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | David Bajor, MD | 49 | 2018-12-07 | 2025-01-23 |
| CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study - Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2018-06-01 | 2018-08-01 | |
| 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Daunorubicin Hydrochloride - Untreated Adult Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2015-12-01 | 2018-07-03 | |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation - Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 48 | 2015-09-01 | 2024-09-19 |
Leukemia, Myeloid, Acute (2) · Pancreatic Neoplasms (2) · Sarcoma, Myeloid (2) · Adenocarcinoma of Lung (1) · Biliary Tract Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Gallbladder Neoplasms (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Ovarian Neoplasms (1)
Wake Forest University Health Sciences (5) · David Bajor, MD (1) · Northwestern University (1) · University of Michigan Rogel Cancer Center (1)
United States (7)
Bayard Powell (1) · Bayard Powell, MD (1) · David Bajor, MD (1) · Devalingam Mahalingam (1) · Rakhee Vaidya, M.B.B.S. (1) · Stefan Grant (1) · Timothy Pardee (1) · Vaibhav Sahai, MBBS, MS (1)
P30CA012197 (5), P30CA060553 (1)